Head-To-Head Contrast: DBV Technologies (NASDAQ:DBVT) versus Genenta Science (NASDAQ:GNTA)

DBV Technologies (NASDAQ:DBVT) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Insider & Institutional Ownership

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 15.1% of Genenta Science shares are held by institutional investors. 1.9% of DBV Technologies shares are held by company insiders. Comparatively, 29.0% of Genenta Science shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

DBV Technologies has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500.

Profitability

This table compares DBV Technologies and Genenta Science’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-815.73%	-106.07%	-76.17%
Genenta Science	N/A	N/A	N/A

Earnings and Valuation

This table compares DBV Technologies and Genenta Science”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$15.73 million	5.02	-$72.73 million	($4.50)	-0.85
Genenta Science	N/A	N/A	-$12.60 million	N/A	N/A

Genenta Science has lower revenue, but higher earnings than DBV Technologies.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for DBV Technologies and Genenta Science, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	0	0	2	0	3.00
Genenta Science	0	0	1	0	3.00

DBV Technologies currently has a consensus target price of $22.50, indicating a potential upside of 485.94%. Genenta Science has a consensus target price of $25.00, indicating a potential upside of 371.70%. Given DBV Technologies’ higher probable upside, analysts clearly believe DBV Technologies is more favorable than Genenta Science.

Summary

Genenta Science beats DBV Technologies on 6 of the 10 factors compared between the two stocks.

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.